GKOS

GlaukosC

NYSE / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

Probability

Target price

$145.00

+30.9% vs current

Most likely

Base case

Probability

Target price

$130.00

+17.3% vs current

B-

Bear case

Probability

Target price

$105.00

-5.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

News flow into late April 2026 was modestly constructive because it included Epioxa commercial availability, a permanent J-code announcement, and scientific-presentation activity. However, this was a scheduled post-earnings T+1 run that arrived before the checked company sources showed the actual Q1 2026 release; therefore earnings surprise, guidance change, analyst revision activity, and true post-print price reaction were unavailable as of April 29, 2026 UTC. Social-context coverage was not provided in the packet, so this remains a cautious monitoring view rather than a high-conviction reaction call.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-29eventQ1 2026 earnings release is scheduled for April 29 after market closeMedium impact

As of April 29, 2026 UTC, the company source checked only confirmed that Glaukos planned to release first-quarter 2026 financial results after the market close on April 29, 2026, with the webcast at 4:30 p.m. ET, so the actual earnings release, surprise versus consensus, and immediate post-print reaction were not yet available from sources checked.

2026-07-01catalystEpioxa launch plus reimbursement setup can improve corneal-health adoptionHigh impact

Glaukos announced commercial availability of Epioxa on March 19, 2026, and then disclosed a permanent HCPCS J-code effective July 1, 2026 on April 15, 2026. That sequence supports a real launch-to-reimbursement path, while the March 2026 investor presentation also framed successful commercialization of iDose TR and Epioxa as core growth drivers and showed solid liquidity with no debt at December 31, 2025 [#8-K-2026-03-02].

2026-09-30catalystiDose TR and broader dropless pipeline remain the main multi-quarter growth thesisHigh impact

The March 2026 investor presentation highlighted two large unmet-need markets in interventional glaucoma and keratoconus, 12 commercialized products, 13 disclosed pipeline programs, roughly $800 million invested in R&D since 2018, and management's focus on successfully commercializing iDose TR and Epioxa [#8-K-2026-03-02]. That supports a durable platform narrative, but near-term proof still depends on procedure uptake, reimbursement, and execution.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology